Recent studies conducted over the past two years regarding the blood-thinner Pradaxa have found that the medication poses a greater risk of gastrointestinal bleeding than other similar medications.
The Food and Drug Administration (FDA) originally approved Pradaxa for preventing blood clots and strokes in patients suffering from non-valvular fibrillation in 2011. However, the following year, the FDA announced that it had begun investigations into a number of incidents in which patients taking Pradaxa suffered internal bleeding. The FDA noted that the initial clinical trials of Pradaxa showed similar side effects to other blood-thinners; however, the agency would revisit the medication to determine whether the risks outweighed the potential benefits.
As of July 2014, the BMJ published a study in which Pradaxa was found to cause a higher risk of severe internal bleeding problems. Additionally, in October of the same year, a study published in Circulation indicated that while Pradaxa may lower the risk of certain types of stroke in some patients, it also increases the chance of major stomach bleeding.
At Kahn Roven, our experienced Woodland Hills product defect legal team can help you understand your legal rights if you or a loved one has suffered serious or even fatal bleeding problems caused by a defective medication. Call our office to schedule a free consultation at (888) 366-5854. We will fight to help you obtain your rightful compensation and so that the at-fault manufacturer could be held accountable.